Instil Bio logo

Instil BioNASDAQ: TIL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 March 2021

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$158.64 M
-94%vs. 3y high
50%vs. sector
-vs. 3y high
-vs. sector
-81%vs. 3y high
37%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 4 min ago
$24.31-$2.38(-8.92%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

TIL Latest News

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
globenewswire.com05 November 2024 Sentiment: POSITIVE

Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. “We remain confident that delivering a TIL-based product with a higher proportion of tumor-reactive T cells is the key to extending the clinical application of TILs across a broader range of solid tumors,” said David Stojdl, Ph.D.

Instil Bio Stock Skyrockets 641% in One Week: Here's Why
zacks.com16 September 2024 Sentiment: POSITIVE

A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.

Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
fool.com14 September 2024 Sentiment: POSITIVE

Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1 testing, but a similar candidate from Summit Therapeutics recently outperformed Keytruda.

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
seekingalpha.com13 September 2024 Sentiment: POSITIVE

Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive advantages of IMM2510 would be the ability to bind to other VEGF ligands beyond that of VEGF-A only and to have enhanced ADCC killing. In-licensing deal with ImmuneOnco also brings on board next-generation anti-CTLA-4 antibody IMM27M, which also has enhanced ADCC killing.

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com13 August 2024 Sentiment: POSITIVE

DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update.

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
globenewswire.com01 August 2024 Sentiment: POSITIVE

DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a definitive agreement pursuant to which Instil is in-licensing ex-China development and commercial rights to ImmueOnco's proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-generation anti-CTLA-4 antibody, IMM27M.

What Makes Instil Bio (TIL) a New Buy Stock
Zacks Investment Research27 March 2024 Sentiment: POSITIVE

Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)
Zacks Investment Research31 August 2023 Sentiment: POSITIVE

The heavy selling pressure might have exhausted for Instil Bio, Inc. (TIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

What type of business is Instil Bio?

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

What sector is Instil Bio in?

Instil Bio is in the Healthcare sector

What industry is Instil Bio in?

Instil Bio is in the Biotechnology industry

What country is Instil Bio from?

Instil Bio is headquartered in United States

When did Instil Bio go public?

Instil Bio initial public offering (IPO) was on 19 March 2021

What is Instil Bio website?

https://instilbio.com

Is Instil Bio in the S&P 500?

No, Instil Bio is not included in the S&P 500 index

Is Instil Bio in the NASDAQ 100?

No, Instil Bio is not included in the NASDAQ 100 index

Is Instil Bio in the Dow Jones?

No, Instil Bio is not included in the Dow Jones index

When was Instil Bio the previous earnings report?

No data

When does Instil Bio earnings report?

The next expected earnings date for Instil Bio is 21 March 2025